Market Overview - The Chinese medicine sector experienced a decline of 0.36% on September 25, with Enwei Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers included: - Weikang Pharmaceutical, closing at 25.25 with a rise of 9.83% and a trading volume of 135,600 shares, totaling 329 million yuan [1] - Yisheng Pharmaceutical, closing at 7.98 with a rise of 1.53% and a trading volume of 80,000 shares, totaling 6.41 million yuan [1] - Major decliners included: - Enwei Pharmaceutical, closing at 32.25 with a drop of 3.09% and a trading volume of 8,950 shares, totaling 2.91 million yuan [2] - Zhendong Pharmaceutical, closing at 6.85 with a drop of 2.97% and a trading volume of 508,400 shares [2] Capital Flow - The Chinese medicine sector saw a net outflow of 462 million yuan from institutional investors, while retail investors contributed a net inflow of 315 million yuan [2] - The table of capital flow indicates that: - Wanbangde had a net inflow of 23.44 million yuan from institutional investors, but a net outflow of 29.29 million yuan from retail investors [3] - Jilin Aodong experienced a net inflow of 21.10 million yuan from institutional investors, with outflows from both retail and speculative investors [3]

Financing Activities - On September 12, Jianmin Group (600976) had a financing buy-in of 17.1361 million yuan and a financing repayment of 16.3358 million yuan, resulting in a net financing buy of 800,300 yuan, with a financing balance of 210 million yuan [1] - Over the past three trading days, the cumulative net buy has reached 3.2865 million yuan, and in the last 20 trading days, there have been 12 days with net financing buy [1] Financing and Margin Data - The financing balance on September 12 was 210 million yuan, which represents an increase of 0.37% compared to the previous day [4] - The financing balance has shown a consistent upward trend, with notable increases of 6.60% and 6.13% on September 9 and September 8, respectively [4] Margin Trading - On September 12, there were no shares sold short, but 400 shares were repaid, resulting in a net short buy of 400 shares, with a remaining short balance of 17,400 shares [3] - The short balance on September 12 was valued at 736,500 yuan [3]

Market Overview - The Chinese traditional medicine sector rose by 1.24% on September 8, with Jianmin Group leading the gains [1] - The Shanghai Composite Index closed at 3826.84, up 0.38%, while the Shenzhen Component Index closed at 12666.84, up 0.61% [1] Top Performers - Jianmin Group (600976) closed at 43.36, up 4.23% with a trading volume of 66,000 shares and a turnover of 280 million yuan [1] - Qizheng Pharmaceutical (002287) closed at 28.64, up 4.15% with a trading volume of 173,000 shares [1] - Zhaoli Pharmaceutical (300181) closed at 18.86, up 3.97% with a trading volume of 222,100 shares [1] - Yiling Pharmaceutical (002603) closed at 17.03, up 3.90% with a trading volume of 447,300 shares [1] Underperformers - ST Xiangxue (300147) closed at 11.05, down 1.69% with a trading volume of 211,600 shares [2] - Zhendong Pharmaceutical (300158) closed at 7.96, down 0.50% with a trading volume of 384,600 shares [2] - Taiji Group (600129) closed at 22.29, down 0.45% with a trading volume of 180,300 shares [2] Capital Flow - The traditional medicine sector experienced a net outflow of 40.80 million yuan from institutional investors and 45.85 million yuan from speculative funds, while retail investors saw a net inflow of 86.65 million yuan [2] - Zhaoli Pharmaceutical (300181) had a net inflow of 62.71 million yuan from institutional investors, while retail investors had a net outflow of 54.18 million yuan [3] - Jianmin Group (600329) saw a net inflow of 28.68 million yuan from institutional investors, with retail investors experiencing a net outflow of 22.12 million yuan [3]

Group 1 - Huazhong Securities has been approved to issue subordinate corporate bonds with a total face value of no more than 10 billion yuan [1] - Jinbei Automotive plans to invest 240 million yuan to establish an automotive industry investment fund focusing on electrification, intelligence, and low carbon [1] - Linyang Energy is expected to win a bid for a 244 million yuan metering equipment project from Southern Power Grid [1][2] Group 2 - Renfu Pharmaceutical's subsidiary has received drug registration certificates for two products, including a medication for acute hypotension [3][4] - Nanjing Steel plans to distribute a cash dividend of 0.1186 yuan per share [5][6] - Pairui Co. has signed a strategic cooperation agreement with Xi'an Power Electronics Research Institute to develop power devices [7][8] Group 3 - Haixing Electric is expected to win a bid for a 214 million yuan metering equipment project from Southern Power Grid [9][10] - Kuangda Technology is planning a change in control, leading to a continued suspension of its stock [11][12] - Samsung Medical is expected to win a bid for a 274 million yuan metering equipment project from Southern Power Grid [13][14] Group 4 - Jiukang Bio has obtained a medical device registration certificate for a specific diagnostic kit [15][16] - Hechuan Technology's minority shareholder plans to transfer a 13% stake in a subsidiary [17][18] - DiAo Micro has launched a new eUSB2 repeater product for various electronic applications [19][20] Group 5 - David Medical's electric surgical table registration application has been accepted [21][22] - Hangxin Technology plans to apply for a total of 280 million yuan in bank credit [23][24] - Liyuan Technology's non-independent director has resigned [25][26] Group 6 - Ningbo Construction's subsidiary has won a construction project bid worth 729 million yuan [27][28] - Huaren Pharmaceutical's subsidiary has received approval for a raw material drug [29][30] - Suwen Electric plans to distribute a cash dividend of 1 yuan per 10 shares [31][32] Group 7 - Solar Energy has received 1.692 billion yuan in renewable energy subsidies [33][34] - Wangli Security has obtained a patent for a new lock structure [35][36] - Zhejiang Energy's vice chairman has resigned due to age reasons [37][38] Group 8 - Beilu Pharmaceutical's subsidiary has passed GMP certification in Brazil [39][40] - Zhejiang Communications has a subsidiary that is expected to win a highway project bid [41][42] - Xinzhi Group has received a government subsidy of 11.1978 million yuan [43][44] Group 9 - Dong'an Power's engine sales in August increased by 3.44% year-on-year [45][46] - Baiyun Mountain's subsidiary has passed the consistency evaluation for two generic drugs [47][48] - Yipin Hong's subsidiary has received a drug registration certificate for a specific injection [49][50] Group 10 - Far East Holdings' subsidiary has won multiple contracts totaling 1.689 billion yuan [51][52] - Good Housekeeping's shareholder plans to reduce holdings by up to 3.5 million shares [53][54] - Guanghong Technology's shareholders have set a transfer price of 23.33 yuan per share [55][56] Group 11 - Keli Sensor plans to acquire 45% of Huahong Technology's shares for 122 million yuan [57][58] - Jianmin Group's furosemide oral solution has been approved for market launch [59][60] - Jinghua Laser's directors plan to reduce their holdings by up to 143,420 shares [61][62] Group 12 - Zhuyue Group is planning a share transfer that will change its controlling shareholder [63][64] - Terid has pre-bid for two projects totaling approximately 698 million yuan [65][66] - Zhonghuan Hailu is planning a change in control, leading to a continued suspension of its stock and convertible bonds [67][68] Group 13 - Great Wall Motors reported August sales of 115,600 vehicles, a year-on-year increase of 22.33% [69][70] - Guizhou Tire's controlling shareholder has committed not to reduce holdings for 12 months [71][72] - San Da Membrane's shareholder plans to reduce holdings by up to 1% of the company's shares [73][74] Group 14 - Chint Electric has decided to terminate the spin-off of its subsidiary for listing [75][76] - Jusaylong's shareholder plans to reduce holdings by up to 1% of the company's shares [77][78]

Group 1 - The core point of the announcement is that Jianmin Pharmaceutical Group has received approval for the oral solution of Furosemide, which is a diuretic used for treating edema and hypertension [1][2]. - The drug is classified as a prescription medication and is registered as a Class 3 chemical drug in China, with a shelf life until August 25, 2030 [1][2]. - The oral solution form of Furosemide is particularly suitable for children, enhancing medication safety and compliance compared to traditional tablet and injection forms [2]. Group 2 - The total research and development investment for the Furosemide oral solution reached approximately RMB 8.0523 million as of July 31, 2025 [2]. - In the Chinese market, Furosemide has various formulations, including tablets and injections, with sales figures for Furosemide reaching RMB 690 million in 2022, RMB 735 million in 2023, and RMB 603 million in 2024 [3]. - The approval of the Furosemide oral solution is expected to enrich the company's product line and enhance its core competitiveness, although short-term impacts on financial performance are anticipated to be limited [3].

Group 1 - The core point of the article is that Jianmin Group has received approval from the National Medical Products Administration for its furosemide oral solution to be marketed [2] Group 2 - The announcement was made on the evening of September 1 [2] - The approval signifies a significant milestone for the company's product development and market entry [2]

证券代码：600976 证券简称：健民集团 公告编号：2025-033 健民药业集团股份有限公司 关于呋塞米口服溶液获批上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，健民药业集团股份有限公司（以下简称"公司"）从国家药品监督管 理局网站获悉，公司研发的呋塞米口服溶液获批上市。现将相关情况公告如下： 一、药品获批上市的主要内容 药物名称：呋塞米口服溶液 剂型：口服溶液剂 药品批准文号：国药准字 H20255196 药品批准文号有效期：至 2030 年 08 月 25 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 申请事项：药品注册（境内生产） 二、药品研发及相关情况 规格：60ml:0.6g 药物名称：呋塞米口服溶液 注册分类：化药 3 类 包装规格：1 瓶/盒 处方药/非处方药：处方药 上市许可持有人：健民药业集团股份 ...

Core Viewpoint - The approval of the oral solution of Furosemide by Jianmin Group represents a significant advancement in the treatment options for conditions such as heart failure, liver cirrhosis, and kidney-related edema, as well as hypertension [1] Company Summary - Jianmin Group has received approval from the National Medical Products Administration for its Furosemide oral solution [1] - The oral solution is a high-efficiency diuretic, which is more suitable for children compared to traditional tablet and injection forms, enhancing medication safety and adherence [1] - The developed product has the same active ingredients, excipients, dosage form, specifications, indications, administration routes, and dosages as the reference original preparation, indicating its clinical application value [1] Industry Summary - The introduction of the oral solution will provide more treatment options in the relevant disease areas, potentially impacting the market for diuretics and related medications [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its oral solution of Furosemide, a potent diuretic used for treating edema related to heart failure, liver cirrhosis, and kidney diseases, as well as hypertension [1] Group 1 - The oral solution formulation is more suitable for children compared to traditional tablet and injection forms, enhancing medication safety and adherence [1]

Market Overview - The Shanghai Composite Index closed at 3857.93 points, above the annual line, with a change of 0.37% [1] - The total trading volume of A-shares reached 28,301.97 billion yuan [1] Stocks Breaking Annual Line - A total of 22 A-shares have surpassed the annual line today, with notable stocks including Guoan Co., Transsion Holdings, and ST Huawen, showing divergence rates of 6.70%, 5.14%, and 4.43% respectively [1] - Stocks with smaller divergence rates that just crossed the annual line include Changjiang Electric, ST Zhongzhuang, and Laobaigan Liquor [1] Top Divergence Rates - The top three stocks with the highest divergence rates are: - Guoan Co. (10.07% increase, 6.70% divergence) - Transsion Holdings (7.17% increase, 5.14% divergence) - ST Huawen (4.86% increase, 4.43% divergence) [1] Additional Stock Performance - Other notable stocks include: - Shenyang Machine Tool (4.49% increase, 3.75% divergence) - Shangong Shenbei (4.20% increase, 3.64% divergence) - ST Boda (4.10% increase, 3.48% divergence) [1]